医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

InnoCare to Host 2020 Full Year Earnings Call on March 29, 2021

2021年03月11日 PM11:34
このエントリーをはてなブックマークに追加


 

BEIJING

InnoCare Pharma (HKEX: 09969), a leading biopharmaceutical company focusing on cancer and autoimmune diseases, today announced that it will host a conference call to discuss the 2020 full year financial results and provide a corporate update at 9:00 a.m. Beijing time on March 29, 2021. Before the call, the Company will announce the financial results for the full year ended December 31, 2020.

Conference Call Information

InnoCare will host a conference call on March 29, 2021 at 9:00 a.m. Beijing time. Participants must register in advance of the conference call. Details are as follows:

Registration Link: http://apac.directeventreg.com/registration/event/4956225

Conference ID: 4956225

The call will be conducted in English.

Upon registering, each participant will receive a dial-in number, Direct Event passcode, and a unique access PIN, which can be used to join the conference call.

A replay will be available on the Company’s website at Investor Relations page.

About InnoCare

InnoCare is a commercial stage biopharmaceutical company committed to discovering, developing, and commercializing first-in-class and/or best-in-class drugs for the treatment of cancer and autoimmune diseases. We strategically focus on lymphoma, solid tumors, and autoimmune diseases with high unmet medical needs in China and worldwide. InnoCare has branches in Beijing, Nanjing, Shanghai, Guangzhou, New Jersey, and Boston.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210311005638/en/

CONTACT

Media

Chunhua Lu

86-10-66609879

chunhua.lu@innocarepharma.com

Investor Relations

86-10-66609999

ir@innocarepharma.com

同じカテゴリーの記事 

  • La Jolla Institute for Immunology and RevolKa started a Research Collaboration
  • U.S. FDA Approves Subcutaneous Administration of Takeda’s ENTYVIO® (vedolizumab) for Maintenance Therapy in Moderately to Severely Active Crohn’s Disease
  • ESCMID Global 2024: Shionogi presents real-world data demonstrating efficacy of Fetcroja® / Fetroja® (cefiderocol) in critically ill patients with certain difficult-to-treat bacterial infections
  • Renesas’ New FemtoClock™ 3 Timing Solution Delivers Industry’s Lowest Power and Leading Jitter Performance of 25fs-rms
  • 成人向け予防接種プログラムは初期投資の19倍もの社会経済的価値をもたらすとの新レポートを発表